Chronic Hand Eczema Market

Market Overview:

The 7 major chronic hand eczema markets reached a value of US$ 12.6 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 26.8 Billion by 2034, exhibiting a growth rate (CAGR) of 7.1% during 2024-2034.

The chronic hand eczema market has been comprehensively analyzed in IMARC's new report titled "Chronic Hand Eczema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic hand eczema refers to a persistent and distressing dermatological condition characterized by inflammation and irritation of the skin on the hands. It is often exacerbated by various factors, such as genetic predisposition, frequent exposure to irritants like detergents, allergens, and environmental triggers. The symptoms of this ailment can vary in intensity but commonly include redness, itching, dryness, painful cracks, and sometimes even blisters. The affected skin may become thickened and scaly and exhibit a compromised barrier function, leading to increased vulnerability to infections and discomfort in daily activities. The diagnosis of chronic hand eczema typically involves a thorough examination by a dermatologist who considers the patient's medical history, physical symptoms, and potential triggers. In some cases, patch testing might be conducted to identify specific allergens that might be contributing to the condition. Differential diagnosis is important to rule out several other similar skin conditions like psoriasis or fungal infections.

The increasing cases of exposure to irritants and allergens in the environment that can trigger an immune response are primarily driving the chronic hand eczema market. In addition to this, the inflating utilization of topical corticosteroids, emollients, and barrier creams, which provide relief by alleviating symptoms and restoring the skin's protective barrier, is also creating a positive outlook for the market. Moreover, the widespread adoption of phototherapy, involving exposure to ultraviolet light under controlled conditions to mitigate inflammation and suppress the immune responses causing the illness, is further bolstering the market growth. Apart from this, the rising application of lifestyle adjustments and meticulous skin care regimens, since they help to prevent exacerbations of the disease, thereby enhancing treatment outcomes in individuals suffering from the ailment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of systemic therapies and biologic agents to treat patients who do not respond to topical treatments is also augmenting the market growth. These therapeutic medications work by targeting specific parts of the immune system that are linked to inflammation. Furthermore, the escalating demand for advanced interventions like gene therapies, on account of their several benefits, such as long-lasting effects, targeted cellular modifications, fewer systemic adverse reactions, etc., is expected to drive the chronic hand eczema market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the chronic hand eczema market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic hand eczema and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic hand eczema market in any manner.

Recent Developments:

• In March 2024, LEO Pharma A/S revealed for the first time major findings from the DELTA 3 study of delgocitinib cream, an experimental topical pan-Janus kinase (JAK) inhibitor, used for the treatment of chronic hand eczema. The results showed that experimental delgocitinib cream had a safety and effectiveness profile consistent with previous DELTA 1 and 2 trials.

Key Highlights:

• The lifetime prevalence of chronic hand eczema ranges from 8.4% to 41.8% globally.
• Approximately one-tenth of hand eczema patients who visit dermatology centers have severe refractory chronic hand eczema.
• Chronic hand eczema is particularly common in those who work in high-risk industries with consistent water contact to the hands, including health care professionals, hairdressers, cooks, cleaners, and anyone working in manufacturing that involves direct hand work.
• Chronic hand eczema is approximately 3-4 times more common in persons with atopic dermatitis.

Drugs:

Alitretinoin is a compound retinoid that is approved for adult patients suffering from severe chronic hand eczema who have not responded to powerful topical corticosteroids. Two randomized, double-blind, placebo-controlled phase 3 studies have demonstrated the safety and efficacy of oral alitretinoin in individuals with severe chronic hand eczema that has not responded to topical corticosteroids.

Delgocitinib is a first-in-class experimental topical pan-Janus kinase (JAK) inhibitor that suppresses activation of the JAK-STAT pathway, which is important in the immune system and drives the pathogenesis of chronic inflammatory skin diseases10-11. LEO Pharma is currently developing delgocitinib cream for the management of moderate to severe chronic hand eczema in adults.

Gusacitinib (ASN002) is a strong inhibitor of the Janus kinase (JAK) family (JAK1, JAK2, JAK3, and TYK2) as well as the spleen tyrosine kinase. This drug inhibits SYK-JAK, which controls Th2, Th22, Th1, and Th17 cytokines, targeting both immune cells and epithelial cells involved in the pathogenesis of chronic hand eczema.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic hand eczema market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic hand eczema market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic hand eczema marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic hand eczema market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2034?
• What was the country-wise size of the chronic hand eczema market across the seven major markets in 2024 and what will it look like in 2034?
• What is the growth rate of the chronic hand eczema market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chronic hand eczema across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic hand eczema by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic hand eczema by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with chronic hand eczema across the seven major markets?
• What is the size of the chronic hand eczema patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic hand eczema?
• What will be the growth rate of patients across the seven major markets?
   

Chronic Hand Eczema: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic hand eczema drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic hand eczema market?
• What are the key regulatory events related to the chronic hand eczema market?
• What is the structure of clinical trial landscape by status related to the chronic hand eczema market?
• What is the structure of clinical trial landscape by phase related to the chronic hand eczema market?
• What is the structure of clinical trial landscape by route of administration related to the chronic hand eczema market?